Medimmune Limited

Boston Pharmaceuticals, Inc.

University of California

Ping Tsui

James David Marks

Changshou Gao

Nazzareno Dimasi

Ching Ching Leow

Mario A Cepeda

Adrian Schwartz Mittelman

Karen Coffman

Partha S Chowdhury

Melissa Marie Damschroder

Xiaodong Xiao

Ronald Herbst

Reena Varkey

Qun Du

William Dall'Acqua

Jianlong Lou

Stacey Drabic

Jody Lynn Baron

Stephen L Nishimura

Catherine Ettinger

Jodi Karnell

Laura Carter

Brian Michael Naiman

Ryan Fleming

Martin Borrok, Iii

Yanli Wu

Anthony Cormier

Nurten Beyaz-Kavuncu

Lynne Murray

The present invention provides molecules, including proteins, more particularly, immunoglobulins whose in vivo half-lives are altered (increased or decreased) by the presence of an IgG constant domain, or FcRn binding fragment thereof (e.g., an Fc region or hinge-Fc region) (e.g., from a human IgG, e.g., human IgG1), that have modifications of one or more of amino acid residues in at least the CH3 domain.

Molecules with altered neonate Fc receptor binding having enhanced therapeutic and diagnostic properties

The present invention relates to antibodies having activity against a vascular endothelial growth factor (VEGF), and methods of making and using such antibodies.

Nucleic acids encoding anti-VEGF-A antibodies and uses thereof

The present invention relates to bispecific antibodies having activity against a vascular endothelial growth factor (VEGF) and an angiopoietin (ANG), and methods of making and using such bispecific antibodies.

Nucleic acids encoding bispecific anti-VEGF and anti-ANG2 antibodies and uses thereof

This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.

Antibodies specific for IL-21 and uses thereof

Anti-VEGF-A antibodies and uses thereof

Anti-VEGF-A and anti-ANG2 antibodies and uses thereof

Provided are polypeptides comprising a variant IgG Fc domain, wherein the polypeptides exhibit reduced or ablated effector functions (e.g., ADCC and/or CDC) and increased stability and plasma half-life compared to a parent polypeptide. Also provided are compositions, methods of treatment, and methods to diminish Fc-induced effector function in a parent polypeptide.

Molecules with reduced effector function and extended half-lives, compositions, and uses thereof

Growing community of inventors

Gaithersburg, MD, United States of America

Ping Tsui